30 November 2018 - NHS use of Bristol-Myers Squibb’s Opdivo to cut the risk of early stage skin cancer recurrence after surgery has now been approved by the NICE.

The Institute rejected use of the drug in this setting earlier this year on grounds that it was not cost-effective enough, but has now released draft guidelines endorsing its use, with funding via the Cancer Drugs Fund.

According to the firm, the approval marks a change in the treatment of melanoma for patients eligible for surgery, who are currently only monitored to see if their cancer returns, which is known as the “watch and wait” approach.

Read Pharma Times article